AUSTIN, Texas — Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that CEO, Valerie Palmieri, will present at the Women in Bio – New York Chapter meeting at the PRIDE Global Event Space in New York, NY on October 20, 2016 at 6:00PM EST. The presentation, titled “Ovarian Cancer: Changing the Early Detection Paradigm and Controlling Your Destiny” will describe the who, what, why and how of the country’s most deadly gynecologic malignancy. The discussion will include a review of the disease symptoms, and how women can “listen” to their bodies and understand how modern diagnostics help identify cancer early, when it is still highly treatable. Ms. Palmieri will be joined by Sherry Pollex, life partner of NASCAR Sprint Cup driver Martin Truex, Jr and an ovarian cancer thriver. Sherry will review her journey and will highlight how awareness can “truly” make a difference!
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company’s initial in vitro diagnostic test, OVA1®, was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016 Vermillion received FDA clearance for Overa™, a second generation OVA1 test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.
Investor Relations Contact:
LifeSci Advisors LLC